

MEDICINES NOT REIMBURSED THROUGH NATIONAL PRICES AND DIRECTLY COMMISSIONED BY NHS ENGLAND



VERSION 16 PUBLISHED APRIL 2021

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	REIMBURSEMENT C+V OR BLOCK	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
ABACAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET	C+V			✓	
ABACAVIR + LAMIVUDINE + DOLUTEGRAVIR (TRIUVEQ®)	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: B06/Pb/AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET	C+V			✓	
ABACAVIR + LAMIVUDINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET	C+V			✓	
ABALOPARATIDE	MALE AND JUVENILE OSTEOPOROSIS	NHS ENGLAND	DRUGS AFFECTING BONE METABOLISM	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
ABATACEPT	JUVENILE ARTHRITIS-PAEDIATRIC	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/Pg, TA 373	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓		✓	
ABRATERONE	CANCER	NHS ENGLAND	HORMONE ANTAGONISTS	TA259, 387 (SEE ALSO SSC1438) ONLY IN ENZALUTAMIDE NAIVE PATIENTS	NICE/NHS ENGLAND POLICY	NICE	SACT	C+V	✓		✓	
ADALIMUMAB	JUVENILE ARTHRITIS-PAEDIATRIC	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/Pg, TA 373	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓		✓	
ADALIMUMAB	UVEITIS - ADULTS	NHS ENGLAND	CYTOKINE MODULATORS	TA460	NICE	NICE	NICE AUDIT	C+V	✓		✓	
ADALIMUMAB	BEHCETS SYNDROME	NHS ENGLAND	CYTOKINE MODULATORS	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA	C+V			✓	
ADALIMUMAB	HLA B27 ASSOCIATED SUPPURATIVE	NHS ENGLAND	CYTOKINE MODULATORS	NICE TA 392	NICE	NICE	NICE AUDIT	C+V	✓		✓	
ADALIMUMAB	HLA B27 ASSOCIATED SUPPURATIVE	NHS ENGLAND	CYTOKINE MODULATORS	NICE TA 455	NICE	NICE	NICE AUDIT	C+V	✓		✓	
ADALIMUMAB	NON BACTERIAL OSTEOMYELITIS/OSTEITIS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED NHS ENGLAND CLINICAL COMMISSIONING POLICY STATEMENT 201202P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
ADEFOVIR	HEPATITIS B	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED (C0145)	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
AFATINIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA310	NICE	NICE	SACT	C+V			✓	
AFIBERCEPT	CANCER	NHS ENGLAND	CANCER EXCLUSION	NOT ROUTINELY COMMISSIONED (TA307)	AS PER IFR APPROVAL	AS PER IFR APPROVAL	SACT	C+V			✓	
AGALSIDASE ALFA	FABRY'S DISEASE	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE	C+V		✓		
AGALSIDASE BETA	FABRY'S DISEASE	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE	C+V		✓		
ALBUTROPIN	ADULT ONSET GROWTH HORMONE DEFICIENCY	NHS ENGLAND	GROWTH HORMONE & GROWTH HORMONE RECEPTOR ANTAGONIST	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
ALDESLEUKIN	CANCER	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	SACT	N/A		✓		
ALEMTUZUMAB	MULTIPLE SCLEROSIS	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	TA312 AND NHS ENGLAND POLICY STATEMENT 170079P	NICE	NICE	NICE AUDIT	C+V	✓		✓	
ALEMTUZUMAB	PRE-TRANSPLANT IMMUNOSUPPRESSION	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	TRUST GUIDELINES: ISLET TRANSPLANTATION (ONLY IF PROVIDED AT ZERO DRUG COST)	TRUST GUIDELINES	TRUST GUIDELINES	SACT	C+V		✓		
ALEMTUZUMAB	CLL	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	TRUST GUIDELINES: (ONLY IF PROVIDED AT ZERO DRUG COST)	TRUST GUIDELINES	TRUST GUIDELINES	SACT	C+V			✓	
ALEMTUZUMAB	BEHCETS SYNDROME	NHS ENGLAND	CYTOKINE MODULATORS	HIGHLY SPECIALISED CRITERIA ONLY (ONLY IF PROVIDED AT ZERO DRUG COST)	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA	C+V		✓		
ALGLUCOSIDASE ALFA	POMPE DISEASE	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE	C+V		✓		
ALIPOGENE TIPARVOVEC	LIPOPROTEIN LIPASE DEFICIENCY	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
ALISPORIVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
ALPHA MANNOSIDASE RECOMBINANT HUMAN	ALPHA MANNOSIDASE DEFICIENCY	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
AMBRISENTAN	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A11/Pc	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY	C+V		✓		
AMIFAMPRIDINE PHOSPHATE	LEMS	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY: 16009P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
AMIKACIN INHALATION	CYSTIC FIBROSIS	NHS ENGLAND	ANTIBACTERIAL DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
AMIKACIN LIPOSOMAL	CYSTIC FIBROSIS	NHS ENGLAND	ANTIBACTERIAL DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
AMPHOTERICIN LIPOSOMAL	FUNGAL INFECTION	NHS ENGLAND	ANTIFUNGALS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY	Block			✓	
ANABASUM	SCLEDEROMA	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
ANAKINRA	JUVENILE ARTHRITIS-PAEDIATRIC	NHS ENGLAND	CYTOKINE MODULATORS	NICE TA 685 NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/Pg	NICE TA NHS ENGLAND POLICY	NICE TA NHS ENGLAND POLICY	NICE AUDIT NHS ENGLAND POLICY	C+V	✓		✓	
ANAKINRA	PERIODIC FEVERS AND AUTOINFLAMMATORY CONDITIONS	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 170069P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓	✓		
ANAKINRA	CRYOPYRIN ASSOCIATED PERIODIC SYNDROME	NHS ENGLAND	CYTOKINE MODULATORS	CRYOPYRIN ASSOCIATED PERIODIC SYNDROME SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE	C+V		✓		
ANAKINRA	ADULT ONSET STILL'S DISEASE	NHS ENGLAND	CYTOKINE MODULATORS	NICE TA 685 NHS ENGLAND CLINICAL COMMISSIONING POLICY: 170069P	NICE TA NHS ENGLAND POLICY	NICE TA NHS ENGLAND POLICY	NICE AUDIT NHS ENGLAND POLICY	C+V	✓		✓	
ANIDULAFUNGIN	FUNGAL INFECTION	NHS ENGLAND	ANTIFUNGALS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY	Block			✓	
ANIFROLUMAB	SLE	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
ANTILYMPHOCYTE GLOBULIN	APLASTIC ANAEMIA ORGAN TRANSPLANT	NHS ENGLAND	DRUGS USED IN HYPOPLASTIC, HAEMOLYTIC, AND RENAL ANAEMIAS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES		Block		✓		
ANTIPSEUDOMONAS AERUGINOSA IgY	CYSTIC FIBROSIS	NHS ENGLAND	ANTIBACTERIAL DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
ANTITHROMBIN III	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES		Block			✓	

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	REIMBURSEMENT C+V OR BLOCK	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
ANTITHYMOCYTE IMMUNOGLOBULIN	APLASTIC ANAEMIA ORGAN TRANSPLANT	NHS ENGLAND	DRUGS USED IN HYPOPLASTIC, HAEMOLYTIC, AND RENAL ANAEMIAS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES		Block		✓		
ARIMOCLOMOL	NIEMANN-PICK DISEASE	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
ASFOTASE ALFA	HYPOPHOSPHATASIA	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	HST6	NICE	NICE	AS PER MAA	C+V	✓	✓		
ASUNAPREVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
ATACICEPT	SLE	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
ATALUREN	DUCHENNE MUSCULAR DYSTROPHY	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NICE HST3	NICE	NICE	NORTHSTAR DATABASE	C+V	✓	✓		
ATAZANAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET	C+V			✓	
ATAZANAVIR + COBICISTAT (EVOTAZ28)	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET	C+V			✓	
AUTOLOGOUS & ALLOGENIC SERUM EYE DROPS	SEVERE OCULAR SURFACE DISEASE	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 202403P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	Block	✓	✓		
AVACOPAN	ANCA-POSITIVE VASCULITIS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
AXITINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA333 (also refer to circular SSC1508)	NICE	NICE	SACT	C+V		✓		
AZACITIDINE	CANCER	NHS ENGLAND	MYELODYSPLASTIC SYNDROME	TA218	NICE	NICE	SACT	Block		✓		
AZTREONAM LYSINE	CYSTIC FIBROSIS	NHS ENGLAND	ANTIBACTERIAL DRUGS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A01/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	Block			✓*	✓*
AZTREONAM LYSINE	CYSTIC FIBROSIS (CONTINUOUS TREATMENT)	NHS ENGLAND	ANTIBACTERIAL DRUGS	NOT ROUTINELY COMMISSIONED NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16001P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
BARDOLOXOLONE METHYL	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	Block		✓		
BASILIXIMAB	RENAL TRANSPLANT	NHS ENGLAND	CORTICOSTEROIDS AND OTHER IMMUNOSUPPRESSANTS	TA85 & TA99	NICE	NICE		Block		✓		
BECLABUVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
BEDAQUILINE	EXTENSIVELY DRUG RESISTANT TB	NHS ENGLAND	ANTI-TUBERCULOSIS DRUGS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: F04/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓	✓		
BEDAQUILINE	MULTI DRUG RESISTANT TB	NHS ENGLAND	ANTI-TUBERCULOSIS DRUGS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: F04/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓	✓		
BEGLOMAB	GRAFT VERSUS HOST DISEASE	NHS ENGLAND	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
BELACEPT	RENAL TRANSPLANT	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓	✓	
BELUMUMAB	SLE	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NICE TA 397	NICE	NICE	NICE AUDIT	C+V	✓		✓	
BENRALIZUMAB	ASTHMA	NHS ENGLAND	ALLERGEN IMMUNOTHERAPY	NICE TA 585	NICE	NICE	NICE AUDIT	C+V	✓	✓		
BERPRIMINGENIE PERPLASIMD	PERIPHERAL VASCULAR DISEASE	NHS ENGLAND	GENE THERAPY	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
BETAINE	HOMOCYSTEINURIA	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE	C+V		✓		
BEVACIZUMAB	CANCER	CDF	ANTI-NEOPLASTIC DRUGS	CDF POLICY	CDF	CDF	SACT	Block		✓		
BEVACIZUMAB	NEUROFIBROMATOSIS	NHS ENGLAND	ANTI-NEOPLASTIC DRUGS	AS PER NATIONAL PROTOCOL (SEE NF2 SERVICE SPEC)	AS PER NATIONAL PROTOCOL	AS PER NATIONAL PROTOCOL	AS PER NATIONAL PROTOCOL	Block		✓		
BICTECRAVIR (IN COMINATION WITH EMTRICITABINE AND TENOFOVIR ALAFENAMIDE)	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 170131P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET	C+V			✓	
BIMAGRUMAB	INCLUSION BODY MYOSITIS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
BIOTIN	MULTIPLE SCLEROSIS	NHS ENGLAND	VITAMINS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
BLISIBIMOD	SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
BORTEZOMIB	ORGAN REJECTION POST KIDNEY TRANSPLANT	NHS ENGLAND	ANTI-NEOPLASTIC DRUGS	NOT ROUTINELY COMMISSIONED (NHS ENGLAND CLINICAL COMMISSIONING POLICY: A07/P/c)	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
BORTEZOMIB	CANCER	NHS ENGLAND/ CDF	ANTI-NEOPLASTIC DRUGS	TA129, TA228, TA311, TA378, TA573 CDF POLICY NOT ROUTINELY COMMISSIONED (NHS ENGLAND CLINICAL COMMISSIONING POLICY: 170035P, 170074P)	NICE CDF	NICE CDF	SACT	C+V	✓		✓	
BOSENTAN	DIGITAL ULCERS	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A13/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓	✓		
BOSENTAN	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A11/P/c	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY	C+V		✓		
BOSUTINIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 401	NICE	NICE	SACT	C+V	✓		✓	
BOTULINUM TOXIN	FOCAL SPASTICITY IN CHILDREN	NHS ENGLAND	TORSION DYSTONIAS AND OTHER INVOLUNTARY MOVEMENTS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	AS PER POLICY	Block		✓		
BOTULINUM TOXIN***	INTRAVESICAL USE IN SPINAL CORD INJURY	NHS ENGLAND	TORSION DYSTONIAS AND OTHER INVOLUNTARY MOVEMENTS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	AS PER POLICY	Block		✓		
BRIMAPTIDE	ACUTE SENSORINEURAL HEARING LOSS	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
BRINCICIDOFVIR	CYTOMEGALOVIRUS	NHS ENGLAND	CYTOMEGALOVIRUS INFECTION	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
BUROSUMAB	X LINKED HYPOPHOSPHATAEMIA	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	HST 8	NICE	NICE	NICE AUDIT	C+V	✓	✓		
C1 ESTERASE INHIBITORS	HEREDITARY ANGIOEDEMA - ACUTE TREATMENT	NHS ENGLAND	ALLERGIC EMERGENCIES	NHS ENGLAND CLINICAL COMMISSIONING POLICY: B09/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY	C+V			✓	
C1 ESTERASE INHIBITORS	HEREDITARY ANGIOEDEMA - PROPHYLACTIC TREATMENT	NHS ENGLAND	ALLERGIC EMERGENCIES	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16045P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY	C+V	✓	✓		
C1 ESTERASE INHIBITORS	HEREDITARY ANGIOEDEMA - PROPHYLACTIC TREATMENT IN CHILDREN (CINRYZE ONLY)	NHS ENGLAND	ALLERGIC EMERGENCIES	AS PER NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16045P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY	C+V	✓	✓		
CABOTEGRAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A			✓	
CALCIFIDIOL	INBORN ERRORS IN PRIMARY BILE ACID SYNTHESIS	NHS ENGLAND	OTHER ENDOCRINE DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
CANAKINUMAB	CRYOPYRIN ASSOCIATED PERIODIC FEVER SYNDROME	NHS ENGLAND	IMMUNOMODULATING DRUGS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 200209P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY	C+V		✓		
CANAKINUMAB	JUVENILE ARTHRITIS-PAEDIATRIC	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED (TA302)	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
CANNABIDIOL (AS EPIDIOLEX)	DRAVET/LENNOX GESTALT SYNDROME	NHS ENGLAND	CANNABINOIDS	TA615 & TA614	NICE	NICE	NICE AUDIT	C+V	✓	✓		

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	REIMBURSEMENT C+V OR BLOCK	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
CAPLACIZUMAB	THROMBOTIC THROMBOCYTOPENIC PURPURA	NHS ENGLAND	PLATELET DISORDER DRUGS	TA667	NICE	NICE	NICE AUDIT	C+V	✓	✓		
CARGLUMIC ACID	UREA CYCLE DISORDERS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE	C+V		✓		
CARNITINE	CARNITINE DEFICIENCY	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE	C+V				✓
CASPOFUNGIN	FUNGAL INFECTION	NHS ENGLAND	ANTIFUNGALS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY	Block			✓	
CENEGERMIN	NEUTROTROPHIC KERATITIS	NHS ENGLAND	ATMP	NOT ROUTINELY COMMISSIONED (TA 532)	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
CERALIFIMOD	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
CERLIPONASE ALFA	NEURONAL CEROID LIPOFUSCINOSIS	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	HST12	NICE	NICE	NICE AUDIT	C+V	✓	✓		
GETUXIMAB	CANCER	NHS ENGLAND	ANTINEOPLASTIC DRUGS	TA145, TA176 (replaced by TA439), TA473	NICE	NICE	SACT	C+V	✓ (not TA145)		✓	
CHENODEOXYCHOLIC ACID	CEREBROTENDINOUS XANTHOMATOSIS (CTX)	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND CLINICAL COMMISSIONING POLICY 170127P	NHS ENGLAND POLICY	NHS ENGLAND POLICY		C+V	✓	✓		
CHENODEOXYCHOLIC ACID	PRIMARY BILIARY CIRRHOSIS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND CLINICAL COMMISSIONING POLICY 170127P	NHS ENGLAND POLICY	NHS ENGLAND POLICY		C+V	✓	✓		
CHOLIC ACID	INBORN ERRORS IN PRIMARY BILE ACID SYNTHESIS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND CLINICAL COMMISSIONING POLICY 170127P	NHS ENGLAND POLICY	NHS ENGLAND POLICY		C+V	✓	✓		
CIDOFOVIR	CYTOMEGALOVIRUS	NHS ENGLAND	CYTOMEGALOVIRUS INFECTION	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY	Block			✓	
CINACALCET	PRIMARY AND SECONDARY HYPERPARATHYROIDISM	NHS ENGLAND	DRUGS FOR MINERAL BONE DISORDERS	TA117 NHS ENGLAND POLICY 16034P	NICE NHS ENGLAND POLICY	NICE NHS ENGLAND POLICY		Block				✓
CIPROFLOXACIN INHALATION	CYSTIC FIBROSIS	NHS ENGLAND	ANTIBACTERIAL DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
CIPROFLOXACIN LIPOSOMAL (INHALED)	CYSTIC FIBROSIS	NHS ENGLAND	ANTIBACTERIAL DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
CLADRIBINE	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA492, TA616 (Replaces TA492)	NICE	NICE	NICE AUDIT	C+V	✓		✓****	
CLADRIBINE	PULMONARY LANGERHANS HISTIOCYTOSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
CLAZAKIZUMAB	ANTIBODY-MEDICATED REJECTION	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
COBICISTAT	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: F03/P/a/AGREED REGIONAL GUIDELINES	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET	C+V			✓	
CO-CAREDOPA INTESTINAL GEL	PARKINSON'S DISEASE	NHS ENGLAND	NEURODEGENERATIVE CONDITIONS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: D04/P/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓	✓		
COLISTIMETHATE SODIUM	CYSTIC FIBROSIS	NHS ENGLAND	ANTIBACTERIAL DRUGS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A01/P/b TA276	NHS ENGLAND POLICY NICE	NHS ENGLAND POLICY NICE	NHS ENGLAND POLICY NICE AUDIT	Block			✓*	✓*
CONESTAT ALFA	HEREDITARY ANGIOEDEMA - ACUTE TREATMENT ONLY	NHS ENGLAND	ALLERGIC EMERGENCIES	NHS ENGLAND CLINICAL COMMISSIONING POLICY: B09/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY	C+V			✓	
CRIZANILIZUMAB	SICKLE CELL DISEASE	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
CRIZOTINIB	CANCER	NHS ENGLAND/ICDF	PROTEIN KINASE INHIBITORS	NICE TA 406, 422 CDF (TA 529)	NICE CDF	NICE CDF	SACT	C+V	✓		✓	
CYCLIC PYRANOPTERIN MONOPHOSPHATE	MOLYBDENUM COFACTOR DEFICIENCY	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
CYSTEAMINE (MERCAPTAMINE)	NEPHROPATHIC CYSTITIS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE	C+V				
DABRAFENIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA321, TA396 & TA 544	NICE	NICE	SACT	C+V	✓ (not TA321)	✓		
DACLIZUMAB	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
DARBOPOETIN ALPHA	DIALYSIS-INDUCED ANAEMIA	NHS ENGLAND	DRUGS USED IN HYPOPLASTIC, HAEMOLYTIC, AND RENAL ANAEMIAS - IRON OVERLOAD	RENAL DIALYSIS ONLY, INCLUDING VIA OUTPATIENTS, AND ONLY AS PER NICE CG114	TRUST GUIDELINES	TRUST GUIDELINES	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED	Block			✓	
DARUNAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET	C+V			✓	
DARUNAVIR + COBICISTAT	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET	C+V			✓	
DASABUVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA 365	AS PER RUN RATE CARD	AS PER RUN RATE CARD	HEPATITIS C MSD	C+V	✓	✓		
DASATINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NICE TA 425, 426	NICE	NICE	SACT	C+V	✓		✓	
DECITABINE	CANCER	NHS ENGLAND	MYELODYSPLASTIC SYNDROME	NOT ROUTINELY COMMISSIONED (TA270)	AS PER IFR APPROVAL	AS PER IFR APPROVAL	SACT	N/A		✓		
DEFERASIROX	IRON CHELATION IN THALASSAEMIA AND SICKLE CELL	NHS ENGLAND	DRUGS USED IN HYPOPLASTIC, HAEMOLYTIC, AND RENAL ANAEMIAS - IRON OVERLOAD	NHS ENGLAND CLINICAL COMMISSIONING POLICY 16070P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	QUALITY DASHBOARD/ NATIONAL HAEMOGLOBINOPATHY REGISTRY	Block		✓		
DEFERIPRONE**	IRON CHELATION IN THALASSAEMIA AND SICKLE CELL	NHS ENGLAND	DRUGS USED IN HYPOPLASTIC, HAEMOLYTIC, AND RENAL ANAEMIAS - IRON OVERLOAD	NHS ENGLAND CLINICAL COMMISSIONING POLICY 16070P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	QUALITY DASHBOARD/ NATIONAL HAEMOGLOBINOPATHY REGISTRY	Block		✓		
DEFIBROTIDE	HEPATIC VENO-OCCLUSIVE DISEASE	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: P200804P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	Block	✓	✓		
DELAMANID	EXTENSIVELY DRUG RESISTANT TB	NHS ENGLAND	ANTITUBERCULOSIS DRUGS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: F04/P/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓	✓		
DELAMANID	MULTI DRUG RESISTANT TB	NHS ENGLAND	ANTITUBERCULOSIS DRUGS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: F04/P/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓	✓		
DESFERRIOXAMINE**	IRON CHELATION IN THALASSAEMIA AND SICKLE CELL	NHS ENGLAND	DRUGS USED IN HYPOPLASTIC, HAEMOLYTIC, AND RENAL ANAEMIAS - IRON OVERLOAD	NHS ENGLAND CLINICAL COMMISSIONING POLICY 16070P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	QUALITY DASHBOARD/ NATIONAL HAEMOGLOBINOPATHY REGISTRY	Block				
DEXRAZOXANE	ANTHRACYCLINE EXTRAVASATION	NHS ENGLAND	IMMUNOMODULATING DRUGS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES		Block			✓	
DEXRAZOXANE	ANTHRACYCLINE CARDIOTOXICITY	NHS ENGLAND	IMMUNOMODULATING DRUGS	NHS ENGLAND CLINICAL COMMISSIONING POLICY 200204P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY	Block	✓	✓		
DIBOTERMIN ALFA	COMPLEX SPINAL SURGERY	NHS ENGLAND	BONE MORPHOGENETIC PROTEIN	NHS ENGLAND CLINICAL COMMISSIONING POLICY 16063P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AUDIT, BSR REGISTRY	Block		✓		
DICHLORPHENAMIDE	PRIMARY HYPO AND HYPERKALAEMIC PERIODIC PARALYSIS	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
DIDANOSINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET	C+V			✓	
DIMETHYL FUMARATE	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA320	NICE	NICE	NICE AUDIT	C+V	✓		✓****	
DIROXIMEL FUMARATE	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
DOLUTEGRAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: B06/P/a/AGREED REGIONAL GUIDELINES	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET	C+V			✓	
DOMAGROZUMAB	DUCHENNE MUSCULAR DYSTROPHY	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	REIMBURSEMENT C+V OR BLOCK	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
DORAVIRINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 190137P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET	C+V			✓	
DORNASE ALFA	PRIMARY CILIARY DYSKINESIA	NHS ENGLAND	MUCOLYTICS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY 16029P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
DORNASE ALFA	CYSTIC FIBROSIS	NHS ENGLAND	MUCOLYTICS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A011P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	Block			✓*	✓*
DRISAPERSEN	DUCHENNE MUSCULAR DYSTROPHY	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
DUPLUMAB	ASTHMA	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
ECALLANTIDE	HEREDITARY ANGIOEDEMA - ACUTE TREATMENT ONLY	NHS ENGLAND	ALLERGIC EMERGENCIES	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
ECULIZUMAB	ORGAN REJECTION POST KIDNEY TRANSPLANT	NHS ENGLAND	PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY: A07P/b	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
ECULIZUMAB	C3 GLOMERULOPATHY (POST TRANSPLANT)	NHS ENGLAND	PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16054P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓	✓		
ECULIZUMAB	AHUS	NHS ENGLAND	PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03P(S)/HSS/A NICE HST1	NHS ENGLAND POLICY NICE	NHS ENGLAND POLICY NICE	NHS ENGLAND POLICY NICE	C+V	✓	✓		
ECULIZUMAB	PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA	NHS ENGLAND	PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA	NHS NATIONAL SPECIALISED COMMISSIONING TEAM SERVICE SPECIFICATION	NSCT SERVICE SPEC	NSCT SERVICE SPEC	NSCT SERVICE SPEC	C+V		✓		
ECULIZUMAB	DELAYED HAEMOLYTIC TRANSFUSION REACTIONS AND HYPERHAEMOLYSIS IN PATIENTS WITH HAEMOGLOBINOPATHIES	NHS ENGLAND	PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 200602P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓	✓		
EDASALONEXENT	DUCHENNE MUSCULAR DYSTROPHY	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
EDRATIDE	SLE	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
EFAVIRENZ	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONALGUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET	C+V			✓	
EFRALOCTOCOG ALFA / EFMORCTOCOG ALFA / FACTOR VIII FC FUSION PROTEIN (Eloctab®)	HAEMOPHILIA A	NHS ENGLAND	BLOOD-RELATED PRODUCTS	SSC 1652, see also SSC 1818	SSC 1652	SSC 1652	PRODUCTS ON CMU FRAMEWORK	C+V		✓		
EFTRENONACOG ALFA	HAEMOPHILIA B	NHS ENGLAND	BLOOD-RELATED PRODUCTS	SSC 1652	SSC 1652	SSC 1652	PRODUCTS ON CMU FRAMEWORK	C+V		✓		
ELBASVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA 413	AS PER RUN RATE CARD	AS PER RUN RATE CARD	HEPATITIS C MDS	C+V	✓	✓		
EUGLUSTAT	GAUCHER'S DISEASE	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	HST5	NICE	NICE	HIGHLY SPECIALISED DATABASE	C+V		✓		
ELOSULFASE ALFA	MUCOPOLYSACCHARIDOSIS IV TYPE A	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NICE HST2	MANAGED ACCESS AGREEMENT	MANAGED ACCESS AGREEMENT	MANAGED ACCESS AGREEMENT	C+V	✓	✓		
ELTROMBOPAG	ITP IN CHILDREN	NHS ENGLAND	PLATELET DISORDER DRUGS	AS PER ADULT TA 293	NICE	NICE	NICE AUDIT	Block	✓	✓		
ELVTIGRAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONALGUIDELINES	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET	C+V			✓	
ELVUCITABINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A			✓	
EMAPALUMAB	HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
EMICIZUMAB	AS PER BC5H GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 170067P AND 170134P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	PRODUCTS ON CMU FRAMEWORK	C+V		✓		
EMRICASAN	NON-ALCOHOLIC STEATOHEPATITIS (NASH) FIBROSIS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
EMTRICITABINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONALGUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET	C+V			✓	
EMTRICITABINE + TENOFOVIR + DARUNAVIR + COBICISTAT	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: F03P/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET	C+V			✓	
EMTRICITABINE + TENOFOVIR + ELVTIGRAVIR + COBICISTAT	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: F03P/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET	C+V			✓	
EMTRICITABINE + TENOFOVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONALGUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET	C+V			✓	
EMTRICITABINE + TENOFOVIR ALAFENAMIDE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16043P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET	C+V			✓	
EMTRICITABINE + RILPIVIRINE + TENOFOVIR ALAFENAMIDE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16043P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET	C+V			✓	
ENFUVIRTIDE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONALGUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET	C+V			✓	
ENTECAVIR	HEPATITIS B	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA153 & IN PROGRESS	NICE	NICE	NICE AUDIT	C+V			✓	
ENZALUTAMIDE	CANCER	NHS ENGLAND	HORMONE ANTAGONISTS	TA316, TA 377 (SEE ALSO SSC1439) BOTH: ONLY IN ABIRATERONE NAIVE PATIENTS	NICE/NHS ENGLAND POLICY	NICE	SACT	C+V			✓	
EPOETIN ALPHA, BETA, THETA AND ZETA	DIALYSIS-INDUCED ANAEMIA	NHS ENGLAND	DRUGS USED IN HYPOPLASTIC, HAEMOLYTIC, AND RENAL ANAEMIAS - IRON OVERLOAD	RENAL DIALYSIS ONLY, INCLUDING VIA OUTPATIENTS, AND ONLY AS PER NICE CG114	TRUST GUIDELINES	TRUST GUIDELINES	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED	Block				✓
EPOPROSTENOL (s)	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A11P/c	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY	C+V			✓	
EPRATUZUMAB	SLE	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
EPRODISATE	AMYLIDOSIS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
EPTOZEMIB ALFA	COMPLEX SPINAL SURGERY	NHS ENGLAND	BONE MORPHOGENETIC PROTEIN	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
ERLOTINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA162, TA227, TA 374& IN PROGRESS NHSE LETTER	NICE	NICE	SACT	C+V			✓	
ETANERCEPT	JUVENILE ARTHRITIS-PAEDIATRIC	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03P/g; TA 373	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓		✓	
ETANERCEPT	PLAQUE PSORIASIS IN CHILDREN	NHS ENGLAND	CYTOKINE MODULATORS	TA455	NICE	NICE	NICE AUDIT	C+V	✓		✓	
ETELCALCETIDE	HYPERPARATHYROIDISM - DIALYSIS PATIENTS ONLY	NHS ENGLAND	DRUGS FOR MINERAL BONE DISORDERS	TA448	NICE	NICE		Block	✓			✓
ETEPLIRSEN	DUCHENNE MUSCULAR DYSTROPHY	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
ETRAVIRINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONALGUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET	C+V			✓	
EVEROLIMUS (AFINITOR®)	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA421, TA432, TA449, TA498	NICE	NICE	SACT	C+V	✓		✓	
EVEROLIMUS (CERTICAN®)	PREVENTING ORGAN REJECTION IN LIVER TRANSPLANTATION	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED (TA348)	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
EVEROLIMUS (CERTICAN®)	PREVENTING ORGAN REJECTION IN HEART TRANSPLANTATION	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY 16016P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	REIMBURSEMENT C+V OR BLOCK	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
EVEROLIMUS (VOTUBIA®)	SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBULAR SCLEROSIS	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16066P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓	✓		
EVEROLIMUS (VOTUBIA®)	SEIZURES ASSOCIATED WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBULAR SCLEROSIS	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 170093P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓	✓		
EVEROLIMUS (VOTUBIA®)	RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TUBULAR SCLEROSIS	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY STATEMENT B14X09L	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓	✓		
EVINACUMAB	HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA	NHS ENGLAND	LIPID-REGULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
EVOLUCUMAB	HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA	NHS ENGLAND	LIPID-REGULATING DRUGS	AS NICE TA 394 (FOLLOW GUIDANCE FOR HETEROZYGOUS FH)	NICE	NICE	NICE AUDIT	C+V		✓		
EX-VIVO EXPANDED AUTOLOGOUS HUMAN CORNEAL EPITHELIAL CELLS CONTAINING STEM CELLS (HOLOCLEAR)	TREATMENT OF ADULT PATIENTS WITH MODERATE TO SEVERE LIMBAL STEM CELL DEFICIENCY (LSCD), UNILATERAL OR BILATERAL DUE TO PHYSICAL OR CHEMICAL OCULAR BURNS	NHS ENGLAND	ATMP	TA 467	NICE	NICE	NICE AUDIT	C+V	✓	✓		
FACTOR IX	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES	PRODUCTS ON CMU FRAMEWORK	C+V			✓	
FACTOR VII	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES		C+V			✓	
FACTOR VIIIA	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES	PRODUCTS ON CMU FRAMEWORK	C+V			✓	
FACTOR VIII	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES, see also SSC 1818	BCSH GUIDELINES	BCSH GUIDELINES	PRODUCTS ON CMU FRAMEWORK	C+V			✓	
FACTOR VIII INHIBITOR BYPASSING FACTOR (FEIBA)	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES	PRODUCTS ON CMU FRAMEWORK	C+V			✓	
FACTOR XIII	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES	PRODUCTS ON CMU FRAMEWORK	C+V			✓	
FAMPRIDINE	MULTIPLE SCLEROSIS	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY: 16010P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A			✓	✓
FEDRATINIB	MYELOFIBROSIS	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
FENFLURAMINE	DRAVET DISEASE	NHS ENGLAND	CENTRAL NERVOUS SYSTEM	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
FIBRINOGEN	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES		Block			✓	
FIBROBLAST GROWTH FACTOR 1 GENE THERAPY	SOMATOSTATIN ANALOGUE	NHS ENGLAND	SOMATOSTATIN ANALOGUES	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
FINGOLIMOD	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA254 NHS ENGLAND POLICY: D04/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NICE AUDIT	C+V	✓		✓	✓
FITUSIRAN	HAEMOPHILIA A AND B	NHS ENGLAND	ANAEMIAS AND SOME OTHER BLOOD DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
FORIGERIMOD ACETATE	SLE	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
FOSAMPRENAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONAL GUIDELINES	BHVA GUIDELINES (8)	BHVA GUIDELINES (8)	HARS DATASET	C+V			✓	
FOSCARNET	CYTOMEGALOVIRUS	NHS ENGLAND	CYTOMEGALOVIRUS INFECTION	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY	Block			✓	
FOSTEMSAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A			✓	
GALUNISERTIB	CANCER	NHS ENGLAND	MYELODYSPLASTIC SYNDROME	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
GALSULFASE	MUCOPOLYSACCHARIDOSIS	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE	C+V		✓		
GANCICLOVIR	CYTOMEGALOVIRUS	NHS ENGLAND	CYTOMEGALOVIRUS INFECTION	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY	Block			✓	
GANETESPIB	CANCER	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	SACT	N/A			✓	
GEFITINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA192	NICE	NICE	SACT	C+V			✓	
GEVOKIZUMAB	UVEITIS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
GIVOSIRAN	HEPATIC PORPHYRIA	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
GLATIRAMER	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA527 & NHS ENGLAND POLICY: D04/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER NHSE POLICY	Block	✓		✓	✓
GLECAPREVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NICE TA 499	AS PER RUN RATE CARD	AS PER RUN RATE CARD	HEPATITIS C MDS	C+V	✓	✓		
GLUCARPIDASE	METHOTREXATE INDUCED RENAL DYSFUNCTION	NHS ENGLAND	POISONING	NHS ENGLAND CLINICAL COMMISSIONING POLICY: B15/P/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V		✓		
GLYCEROL PHENYLBUTYRATE	UREA CYCLE DISORDERS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	AS PER NHS ENGLAND CIRCULAR SSC 1881 AND LETTER	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V		✓		
GOSURANEMAB	SUPRANUCLEAR PALSY	NHS ENGLAND	CENTRAL NERVOUS SYSTEM	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (LEUKINE® - IMPORT)	ANTIBODY-POSITIVE PULMONARY ALVEOLAR PROTEINOSIS	NHS ENGLAND	DRUGS USED IN NEUTROPENIA	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
GRAZOPREVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA 413	AS PER RUN RATE CARD	AS PER RUN RATE CARD	HEPATITIS C MDS	C+V	✓	✓		
HIV VACCINE	HIV INFECTION PROPHYLAXIS	NHS ENGLAND	VACCINES AND ANTISERA	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
HAEM ARGINATE	HEPATIC PORPHYRIA	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE	C+V		✓		
HUMAN ALPHA-1 PROTEINASE INHIBITOR	EMPHYSEMA	NHS ENGLAND	DRUGS USED FOR EMPHYSEMA	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
HUMAN COAGULATION FACTOR X	FACTOR X DEFICIENCY	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 200208P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY	C+V		✓		
HUMAN HETEROLOGOUS LIVER CELLS	UREA CYCLE DISORDERS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
HUMAN PARATHYROID HORMONE-RELATED PROTEIN ANALOGUE	MALE AND JUVENILE OSTEOPOROSIS	NHS ENGLAND	DRUGS AFFECTING BONE METABOLISM	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
IBALIZUMAB	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A			✓	
ICATIBANT	HEREDITARY ANGIOEDEMA - ACUTE TREATMENT ONLY	NHS ENGLAND	ALLERGIC EMERGENCIES	NHS ENGLAND CLINICAL COMMISSIONING POLICY: B09/P/b and 16045P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY	C+V			✓	
IDEBENONE	DUCHENNE MUSCULAR DYSTROPHY	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
IDEBENONE	LEBERS HEREDITARY OPTIC NEUROPATHY	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED NHS ENGLAND CLINICAL COMMISSIONING POLICY: 200104P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	REIMBURSEMENT C+V OR BLOCK	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
IDURSULFASE	MUCOPOLYSACCHARIDOSIS	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE	C+V		✓		
ILOPROST (5)	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A11/P/c	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY	C+V			✓	
IMATINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA70, TA86, TA251, TA326	NICE	NICE	SACT	C+V			✓	
IMATINIB	CHRONIC GRAFT VERSUS HOST DISEASE	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16069/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V		✓		
IMETELSTAT	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
IMGLUCERASE	GAUCHER'S DISEASE	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE	C+V		✓		
IMLIFIDASE	TRANSPLANT REJECTION PREVENTION IN HLA-SENSITISED PATIENTS	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
INDINAVIR	HIW IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDSHIV ANTI-RETROVIRALS	AGREED REGIONALGUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET	C+V			✓	
INEBILIZUMAB	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
INFLIXIMAB	JUVENILE ARTHRITIS-PAEDIATRIC	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03P/d	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓		✓	
INFLIXIMAB	UVEITIS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED (NHS ENGLAND CLINICAL COMMISSIONING POLICY: D12/P/a & D12/P/a)	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
INFLIXIMAB	CONNECTIVE TISSUE DISEASE - INTERSTITIAL LUNG DISEASE	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED - POLICY IN PROGRESS	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
INFLIXIMAB	CROHN'S DISEASE IN CHILDREN	NHS ENGLAND	CYTOKINE MODULATORS	TA187	NICE	NICE	NICE AUDIT	C+V			✓	
INFLIXIMAB	GRAFT VERSUS HOST DISEASE	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
INFLIXIMAB	RENAL	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
INFLIXIMAB	PULMONARY SARCOIDOSIS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
INFLIXIMAB	REFRACTORY OR PROGRESSIVE NEUROSCARCOIDOSIS	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY 200501P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓	✓		
INFLIXIMAB	HIDRADENITIS SUPPURATIVA	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED - NHS ENGLAND POLICY 16018/P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
INFLIXIMAB	BEHCETS SYNDROME	NHS ENGLAND	CYTOKINE MODULATORS	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA	C+V			✓	
INOTERSEN	AMYLOIDOSIS	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	HS79	NICE	NICE	NICE AUDIT	C+V	✓	✓		
INTERFERON ALFA	HEPATITIS B AND C	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA75	NICE	NICE	NICE AUDIT	Block			✓	
INTERFERON ALFA N3	MIDDLE EAST RESPIRATORY SYNDROME	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
INTERFERON BETA	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA 527, TA624 NHS ENGLAND POLICY: D04/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER NHSE POLICY	Block	✓		✓	✓
INTRAVENOUS NORMAL HUMAN IMMUNOGLOBULINS	MULTIPLE INDICATIONS	NHS ENGLAND	INTRAVENOUS NORMAL HUMAN IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011) IMMUNOGLOBULIN GUIDELINES PUBLISHED 2019 ON MDSAS WEBSITE NHS ENGLAND CLINICAL COMMISSIONING POLICY 190136P	NATIONAL GUIDELINES	NATIONAL GUIDELINES	NATIONAL IMMUNOGLOBULIN DATA BASE	C+V			✓	
ISAVUCONAZOLE	FUNGAL INFECTION (LICENSED INDICATIONS)	NHS ENGLAND	ANTIFUNGALS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY	Block	✓		✓	
IVACAFTOR	CYSTIC FIBROSIS	NHS ENGLAND	MUCOLYTICS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 200810P & 200809P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V			✓	
IXAZOMIB	AMYLOIDOSIS	NHS ENGLAND	CANCER EXCLUSION	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
IXAZOMIB	MULTIPLE MYELOMA	NHS ENGLAND	CANCER EXCLUSION	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A	✓	✓		
LAMIVUDINE	HEPATITIS B	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	CD165	NICE	NICE	NICE AUDIT	C+V			✓	✓
LAMIVUDINE	HIW IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDSHIV ANTI-RETROVIRALS	AGREED REGIONALGUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET	C+V			✓	
LANADELUMAB	HEREDITARY ANGIOEDEMA	NHS ENGLAND	ALLERGIC EMERGENCIES	TA806	NICE	NICE	NICE AUDIT	C+V	✓	✓		
LANREOTIDE	CANCER	NHS ENGLAND	SOMATOSTATIN ANALOGUES	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED	Block				✓
LANREOTIDE	CONGENITAL HYPERINSULINISM	NHS ENGLAND	SOMATOSTATIN ANALOGUES	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY		Block		✓		
LANREOTIDE***	ACROMEGALY	NHS ENGLAND	SOMATOSTATIN ANALOGUES	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED	Block		✓		✓
LANTHANUM CARBONATE	ADULT RENAL DIALYSIS ONLY	NHS ENGLAND	PHOSPHATE BINDING AGENTS		TRUST GUIDELINES	TRUST GUIDELINES		Block				✓
LAPATINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	SACT	N/A			✓	
LAQUINIMOD	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A			✓	
LARONIDASE	MUCOPOLYSACCHARIDOSIS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE	C+V		✓		
LEBRIKIZUMAB	ASTHMA	NHS ENGLAND	ALLERGEN IMMUNOTHERAPY	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
LENALIDOMIDE	CANCER	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA171, TA322, TA587, TA586, TA627, TA680	NICE	NICE	SACT	C+V	✓	✓	✓	
LENALIDOMIDE	POEMS	NHS ENGLAND	IMMUNOMODULATING DRUGS	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY		C+V			✓	
LERONILIMAB	HIW IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDSHIV ANTI-RETROVIRALS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A			✓	
LETERMOVIR	CYTOMEGALOVIRUS	NHS ENGLAND	CYTOMEGALOVIRUS INFECTION	TA 591	NICE	NICE	NICE AUDIT	C+V	✓	✓		
LEVOPLOXACIN (INHALED)	CYSTIC FIBROSIS	NHS ENGLAND	ANTIBACTERIAL DRUGS	NHS ENGLAND POLICY 170078P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	Block				
LEVOKETOCONAZOLE	CUSHING'S DISEASE	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
LIXIVAPTAN	HYPONATRAEMIA AND OTHER ENDOCRINE USES	NHS ENGLAND	POSTERIOR PITUITARY HORMONES AND ANTAGONISTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
LOMITAPIDE	HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA	NHS ENGLAND	LIPID-REGULATING DRUGS	NHS ENGLAND POLICY 170059P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V		✓		
LONAFARNIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
LOPINAVIR + RITONAVIR	HIW IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDSHIV ANTI-RETROVIRALS	AGREED REGIONALGUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET	C+V			✓	
LUMACAFTOR AND IVACAFTOR	CYSTIC FIBROSIS	NHS ENGLAND	MUCOLYTICS	NHS ENGLAND URGENT POLICY STATEMENT 200810P & 200809P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY	C+V			✓	
LUSPATERCEPT	CANCER	NHS ENGLAND	MYELODYSPLASTIC SYNDROME	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
MACimorelin	GROWTH FAILURE	NHS ENGLAND	GROWTH HORMONE & GROWTH HORMONE RECEPTOR ANTAGONIST	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
MACITENTAN	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A11/P/c	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY	C+V		✓		
MANNITOL	CYSTIC FIBROSIS	NHS ENGLAND	MUCOLYTICS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A01/P/b TA266	NHS ENGLAND POLICY NICE	NHS ENGLAND POLICY NICE	NHS ENGLAND POLICY NICE AUDIT	Block			✓	
MARALIXIBAT	ALAGILLE SYNDROME	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	REIMBURSEMENT C+V OR BLOCK	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
MARAVIROC	HIW IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONALGUIDELINES	BHVA GUIDELINES (8)	BHVA GUIDELINES (8)	HARS DATASET	C+V			✓	
MARAVIROC	NATALIZUMAB INDUCED PML	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY STATEMENT 170406P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A			✓	
MARIBAVIR	CYTOMEGALOVIRUS	NHS ENGLAND	CYTOMEGALOVIRUS INFECTION	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
MASITINIB	PANCREATIC CANCER/GIST	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
MECASERMIN	GROWTH FAILURE	NHS ENGLAND	GROWTH HORMONE & GROWTH HORMONE RECEPTOR ANTAGONIST	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY	Block		✓		
MEPOLIZUMAB	ASTHMA, EOSINOPHILIC ASTHMA	NHS ENGLAND	ALLERGEN IMMUNOTHERAPY	TA431, ta871	NICE	NICE	NICE AUDIT	C+V	✓	✓		
MERCAPTAMINE HCL VISCOSUS EYEDROPS	CORNEAL CYSTINE DEPOSITS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED NHS ENGLAND CLINICAL COMMISSIONING POLICY: 292897P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
METRELEPTIN	DYSLIPIDAEMIA	NHS ENGLAND	OTHER ENDOCRINE DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
METRELEPTIN	CONGENITAL LEPTIN DEFICIENCY	NHS ENGLAND	OTHER ENDOCRINE DRUGS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 170095P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY	C+V		✓		
METRELEPTIN	LYPODYSTROPHY	NHS ENGLAND	OTHER ENDOCRINE DRUGS	HST14	NICE	NICE	NICE AUDIT	C+V	✓	✓		
MEKLETINE	NON DYSTROPHIC MYOTONIA	NHS ENGLAND	NEUROMUSCULAR DISORDERS	AS PER NHS ENGLAND CIRCULAR SSC 2001 AND LETTER	AS PER BLUETEQ FORM	AS PER BLUETEQ FORM	AS PER BLUETEQ FORM	C+V	✓	✓		
MICAFUNGIN	FUNGAL INFECTION	NHS ENGLAND	ANTIFUNGALS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY	Block			✓	
MIGALASTAT	FABRY'S DISEASE	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NICE HST4	NICE	NICE	HIGHLY SPECIALISED DATABASE	C+V		✓		
MIGLUSTAT	GAUCHER'S DISEASE/ NIEMANN-PICK	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE	C+V		✓		
MOMELOTINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
NATALIZUMAB	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA127 NHS ENGLAND POLICY: D04/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NICE AUDIT	C+V	✓		✓****	
NELFINAVIR	HIW IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONALGUIDELINES	BHVA GUIDELINES (8)	BHVA GUIDELINES (8)	HARS DATASET	C+V			✓	
NEVIRAPINE	HIW IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONALGUIDELINES	BHVA GUIDELINES (8)	BHVA GUIDELINES (8)	HARS DATASET	C+V			✓	
NILOTINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA241, TA251, TA426	NICE	NICE	SACT	C+V	✓	✓	✓	
NINTEDANIB	OVARIAN CANCER	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	SACT	N/A		✓		
NINTEDANIB (OFEV®)	IDIOPATHIC PULMONARY FIBROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA 379	NICE	NICE	NICE AUDIT	C+V	✓	✓		
NINTEDANIB (VARGATEF®)	NON-SMALL-CELL LUNG CANCER	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA347	NICE	NICE	SACT	C+V		✓		
NITAZOXANIDE	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
NITISINONE	ALKAPTONURIA	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE	C+V		✓		
NITISINONE	TYROSINAEMIA	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE	C+V		✓		
NITRIC OXIDE	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES		Block			✓	
NUSINERSEN	SPINAL MUSCULAR ATROPHY	NHS ENGLAND	NEURODEGENERATIVE CONDITIONS	TA588	NICE	NICE	NICE AUDIT	C+V	✓	✓		
OBETICHOIC ACID	PRIMARY BILIARY CIRRHOSIS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	TA443	NICE	NICE	NICE AUDIT	C+V	✓	✓		
OCRELIZUMAB	MULTIPLE SCLEROSIS	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	TA 533, TA 585	NICE	NICE	NICE AUDIT	C+V	✓		✓****	
OCTOCOQ ALFA	HAEMOPHILIA A	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES: See also SSC 1818	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	C+V		✓		
OCTREOLIN	ACROMEGALY	NHS ENGLAND	GROWTH HORMONE & GROWTH HORMONE RECEPTOR ANTAGONIST	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
OCTREOTIDE	CANCER	NHS ENGLAND	SOMATOSTATIN ANALOGUES	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED	Block				✓
OCTREOTIDE	CONGENITAL HYPERINSULINISM	NHS ENGLAND	SOMATOSTATIN ANALOGUES	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY		Block		✓		
OCTREOTIDE***	ACROMEGALY	NHS ENGLAND	SOMATOSTATIN ANALOGUES	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED	Block				✓
OLESOXIME	SPINAL MUSCULAR ATROPHY	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
OLIPUDASE ALFA	ACID SPHINGOMYELINASE DEFICIENCY	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
OMALIZUMAB	ASTHMA	NHS ENGLAND	ALLERGEN IMMUNOTHERAPY	TA278	NICE	NICE	NICE AUDIT	C+V	✓	✓	✓	
OMBITASVIR/PARITAPREVIR/RITONAVIR + DASILNAVIR + RIBAVIRIN	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA 365	AS PER RUN RATE CARD	AS PER RUN RATE CARD	HEPATITIS C MDS	C+V	✓	✓		
OSLUDROSTAT	CUSHING'S DISEASE	NHS ENGLAND	OTHER ENDOCRINE DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
OZANIMOD	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
PACRITINIB	MYELOFIBROSIS	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
PALOVAROTENE	FIBRODYSPLASIA OSSIFICANS PROGRESSIVA	NHS ENGLAND	DRUGS AFFECTING BONE METABOLISM	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
PALIVIZUMAB	RSV PROPHYLAXIS	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	JCVI GUIDELINES PHE SPECIFICATION	AS PER SPECIFICATION	AS PER SPECIFICATION		Block	✓	✓	✓	
PARA-AMINOSALICYLIC ACID	MULTI DRUG RESISTANT TB	NHS ENGLAND	ANTITUBERCULOSIS DRUGS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: F04/P/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V		✓		
PARATHYROID HORMONE	SPECIALIST ENDOCRINOLOGY CONDITIONS	NHS ENGLAND	PARATHYROID HORMONE	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES		Block			✓	
PARENTERAL NUTRITION (HOME USE)	INTESTINAL FAILURE	NHS ENGLAND	PARENTERAL NUTRITION	AS PER BLUETEQ FORM	AS PER BLUETEQ FORM	AS PER BLUETEQ FORM	AUDIT	C+V	✓	✓		
PARENTERAL NUTRITION (INPATIENT USE)	INTESTINAL FAILURE; INADEQUATE/ UNSAFE ENTERAL FEEDING	NHS ENGLAND	PARENTERAL NUTRITION	ONLY WHEN DURATION OF PN IS > 14 DAYS OR INITIATED PRIOR TO ADMISSION. ADULTS: SEE ALSO C032. SEE ALSO 'MANUAL FOR PRESCRIBED SPECIALISED SERVICES'	TRUST GUIDELINES	TRUST GUIDELINES		C+V			✓	
PARICALCITOL	HYPERPARATHYROIDISM	NHS ENGLAND	OTHER ENDOCRINE DRUGS	AS PER CINACALCET	AS PER CINACALCET	AS PER CINACALCET		Block				✓
PARITAPREVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NICE TA 499	AS PER RUN RATE CARD	AS PER RUN RATE CARD	HEPATITIS C MDS	C+V		✓		
PASIREOTIDE	ACROMEGALY	NHS ENGLAND	SOMATOSTATIN ANALOGUES	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY: 16003P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
PASIREOTIDE	CUSHING'S DISEASE	NHS ENGLAND	SOMATOSTATIN ANALOGUES	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A03X03/01	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	Block	✓	✓		
PATISIRAN	AMYLOIDOSIS	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	HST10	NICE	NICE	NICE AUDIT	C+V	✓	✓		

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	T/A/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	REIMBURSEMENT C+V OR BLOCK	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
PAZOPANIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA215 NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY STATEMENT 170117P	NICE	NICE	SACT	C+V			✓	
PEG INTERFERON ALFA	HEPATITIS B AND C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: B07/P/a; TA75, TA96, TA106, TA200, TA 300 CG165	NICE	NICE	NICE AUDIT	Block			✓	
PEGINTERFERON BETA-1A	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	ROUTINELY COMMISSIONED AS PER SSC1534: MULTIPLE SCLEROSIS FIRST LINE DISEASE MODIFYING AGENTS	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NICE AUDIT	Block	✓		✓***	
PEGUNIGALSIDASE ALFA	FABRY'S DISEASE	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
PEGVALIASE	PHENYLKETONURIA	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
PEGVISOMANT	ACROMEGALY	NHS ENGLAND	HYPOTHALMIC & ANTERIOR PITUITARY HORMONES & ANTI-OESTROGENS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16050P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓	✓		
PEMBROLIZUMAB	CANCER INDICATIONS	NHS ENGLAND/CDF	CANCER EXCLUSION	TA 357, TA366, TA428, TA531, TA661, TA683 CDF POLICY (TA 519, TA540, TA553, TA557 & TA600)	NICE CDF	NICE CDF	SACT	C+V	✓		✓	
PEMBROLIZUMAB	DRUG RESISTANT GESTATIONAL TROPHOBLASTIC NEOPLASIA	NHS ENGLAND	CANCER EXCLUSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY STATEMENT: 170027P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V		✓		
PBIRENTASIVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA499	AS PER RUN RATE CARD	AS PER RUN RATE CARD	HEPATITIS C MDS	C+V		✓		
PIRFENIDONE	IDIOPATHIC PULMONARY FIBROSIS	NHS ENGLAND	PULMONARY FIBROSIS	TA 504 (SPECIALIST CENTRE ONLY)	NICE	NICE	NICE AUDIT	C+V	✓	✓		
PLERIXAFOR	STEM CELL MOBILISATION	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 200601P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NUMBER OF PATIENTS TREATED NUMBER OF PATIENTS SUCCESSFULLY TRANSPLANTED STAGE DRUG UTILISED	C+V	✓	✓		
POMALIDOMIDE	CANCER	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA427	NICE	NICE	SACT	C+V	✓	✓	✓	
POMALIDOMIDE	MYELOFIBROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
PONATINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA451	NICE	NICE	SACT	C+V	✓	✓	✓	
PONESMOD	MULTIPLE SCLEROSIS	NHS ENGLAND	DRUGS USED FOR NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
POSACONAZOLE	FUNGAL INFECTION	NHS ENGLAND	ANTIFUNGALS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY	Block		✓	✓	
PRETOMANID	MULTI DRUG RESISTANT TB	NHS ENGLAND	ANTITUBERCULOSIS DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
PROTEIN C	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES	PRODUCTS ON CMU FRAMEWORK	Block		✓	✓	
PROTHROMBIN COMPLEX	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES	PRODUCTS ON CMU FRAMEWORK	Block		✓	✓	
RALTEGRAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET	C+V		✓	✓	
RASBURICASE	HYPERURICAEMIA	NHS ENGLAND	GOUT AND CYTOTOXIC-INDUCED HYPERURICAEMIA	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	Block	Block		✓	✓	
RAVULIZUMAB	PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA	NHS ENGLAND	PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓	✓	
RAXIBACUMAB	INHALED ANTI-RHAX	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓	✓	
REFANALIN	PREVENTION OF DELAYED GRAFT FUNCTION	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓	✓	
REGORAFENIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA488 & TA555	NICE	NICE	SACT	C+V	✓	✓	✓	
REPARIXIN	PREVENTION OF DELAYED GRAFT FUNCTION	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓	✓	
RESLIZUMAB	ASTHMA	NHS ENGLAND	ALLERGEN IMMUNOTHERAPY	TA479	NICE	NICE	NICE AUDIT	C+V	✓	✓	✓	
REVEGLUCOSIDASE ALFA	POMPE DISEASE	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓	✓	
RIGOSERTIB	MDS/PANCREATIC CANCER	NHS ENGLAND	MYELODYSPLASTIC SYNDROME	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓	✓	
RILPIVIRINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET	C+V		✓	✓	
RIMEPORDIDE	DUCHENNE MUSCULAR DYSTROPHY	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓	✓	
RIOCIGUAT	PULMONARY ARTERIAL HYPERTENSION (CTEPH)	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A11/P/c	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V		✓	✓	
RIOCIGUAT	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16055P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V		✓	✓	
RISDIPLAM	SPINAL MUSCULAR ATROPHY	NHS ENGLAND	NEURODEGENERATIVE CONDITIONS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓	✓	
RITONAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET	C+V		✓	✓	
RITUXIMAB	STEROID SENSITIVE NEPHROTIC SYNDROME	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V		✓	✓	
RITUXIMAB	STEROID RESISTANT NEPHROTIC SYNDROME	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V		✓	✓	
RITUXIMAB	PRIMARY SJOGREN'S SYNDROME (PSS)	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY 16048P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	C+V		✓	✓	
RITUXIMAB	CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY 170026P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	C+V		✓	✓	
RITUXIMAB	JUVENILE ARTHRITIS-PAEDIATRIC	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/d	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓	✓	✓	
RITUXIMAB	ACQUIRED HAEMOPHILIA	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: F02/P/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V		✓	✓	
RITUXIMAB	ANCA-POSITIVE VASCULITIS	NHS ENGLAND	CYTOKINE MODULATORS	TA308 NHS ENGLAND POLICY: A13/P/a	NICE/ NHS ENGLAND POLICY	NICE/ NHS ENGLAND POLICY	NICE/ NHS ENGLAND POLICY	C+V	✓	✓	✓	
RITUXIMAB	ANTI-NMDAR AUTOIMMUNE ENCEPHALITIS	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16036P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓	✓	✓	
RITUXIMAB	CONNECTIVE TISSUE DISEASE - INTERSTITIAL LUNG DISEASE	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY 170015P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	C+V		✓	✓	
RITUXIMAB	CYTOPENIA COMPLICATING PRIMARY IMMUNODEFICIENCY	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16044P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V		✓	✓	
RITUXIMAB	CHRONIC GRAFT VERSUS HOST DISEASE	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16069P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V		✓	✓	
RITUXIMAB	SLE	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 200402P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓	✓	✓	
RITUXIMAB	MEMBRANOUS NEPHROPATHY	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY 16047P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	C+V		✓	✓	
RITUXIMAB	DERMATOMYOSITIS AND POLYMYOSITIS (ADULTS)	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16036P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V		✓	✓	
RITUXIMAB	NEUROMYELITIS OPTICA	NHS ENGLAND	CYTOKINE MODULATORS	AS PER SPECIFICATION	AS PER SPECIFICATION	AS PER SPECIFICATION	AS PER SPECIFICATION	C+V		✓	✓	

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	T&P/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	REIMBURSEMENT C+V OR BLOCK	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
RITUXIMAB	ABO-INCOMPATIBLE KIDNEY TRANSPLANTS	NHS ENGLAND	CYTOKINE MODULATORS	AS PER SPECIFICATION	AS PER SPECIFICATION	AS PER SPECIFICATION	AS PER SPECIFICATION	C+V			√	
RITUXIMAB	PEMPHIGUS VULGARIS AND PEMPHIGOID DISEASE	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16035/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V			√	
RITUXIMAB	IMMUNOGLOBIN G4 RELATED DISEASE	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16057/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V			√	
RITUXIMAB	MYASTHENIA GRAVIS	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY STATEMENT 170084/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	√		√	
RITUXIMAB	FOCAL SEGMENTAL GLOMERULOSCLEROSIS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY STATEMENT 1818	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	C+V		√		
RITUXIMAB	DELAYED HAEMOLYTIC TRANSFUSION REACTIONS AND HYPERHAEMOLYSIS IN PATIENTS WITH HAEMOGLOBINOPATHIES	NHS ENGLAND	PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 200602/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	√	√		
RITUXIMAB IV	CANCER	NHS ENGLAND	CYTOKINE MODULATORS	TA65, TA137, TA174, TA193, TA226, TA243 NHS ENGLAND CDF LETTER NHS ENGLAND CLINICAL COMMISSIONING POLICY P200901/P	NICE NHS ENGLAND CDF LETTER NHS ENGLAND POLICY	NICE NHS ENGLAND CDF LETTER NHS ENGLAND POLICY	SACT	C+V			√	
RITUXIMAB SUBCUTANEOUS FORMULATION	CANCER	NHS ENGLAND	CYTOKINE MODULATORS	AS PER CIRCULAR IE ONLY COMMISSIONED FOR FOLLICULAR LYMPHOMA MAINTENANCE TREATMENT	AS PER CIRCULAR	AS PER CIRCULAR	SACT	C+V			√	
RIVIPANSEL SODIUM	HEPATIC VENO-OCCLUSIVE DISEASE	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		√		
RIVIPANSEL SODIUM	SICKLE CELL DISEASE	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		√		
ROMPLOSTIM	ITP IN CHILDREN	NHS ENGLAND	PLATELET DISORDER DRUGS	AS PER ADULT TA 221	NICE	NICE		Block	√	√		
ROPEGINTERFERON ALFA-2b	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		√		
ROXADUSTAT	DIALYSIS-INDUCED ANAEMIA	NHS ENGLAND	DRUGS USED IN HYPOPLASTIC, HAEMOLYTIC, AND RENAL ANAEMIAS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		√		
RURIOCTOCOG ALFA PEGOL	HAEMOPHILIA A	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		√		
RUZASVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		√		
RUXOLITINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA 386	NICE	NICE	SACT	C+V			√	
SACROSIDASE	CONGENITAL SUCRASE ISOMALTAZE DEFICIENCY	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		√		
SAPROPTERIN	ADULTS AND CHILDREN WITH PHENYLKETONURIA	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED (NHS ENGLAND INTERIM CLINICAL COMMISSIONING POLICY: 200896/P)	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		√		
SAPROPTERIN	MATERNAL PHENYLKETONURIA	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E12/Pa	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HIGHLY SPECIALISED DATABASE	C+V		√		
SAQUINAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET	C+V			√	
SATRALIZUMAB	NEUROMYELITIS OPTICA	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		√		
SEBELIPASE ALFA	LYSOSOMAL ACID LIPASE DEFICIENCY	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NOT ROUTINELY COMMISSIONED NICE HST IN PROGRESS	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		√		
SELEXIPAG	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 170104/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V		√		
SETRUSUMAB	OSTEOGENESIS IMPERFECTA	NHS ENGLAND	DRUGS AFFECTING BONE METABOLISM	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		√		
SEVELAMER	ADULT RENAL DIALYSIS ONLY	NHS ENGLAND	PHOSPHATE BINDING AGENTS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES		Block				√
SIPONIMOD	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA656	NICE	NICE	NICE AUDIT	C+V	√	√		
SIROLIMUS (RAPAMUNE)	TRANSPLANT IMMUNOSUPPRESSION ONLY	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	TA481, TA482 NEW PATIENTS ONLY UNTIL FORMAL REPATRIATION AGREED	NICE	NICE	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED	C+V			√*	√*
SODIUM OXYBATE	NARCOLEPSY - PEDIATRIC SERVICES ONLY	NHS ENGLAND	HYPNOTICS & ANXIOLYTICS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16065/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	Block	√	√		
SODIUM PHENYLBUTYRATE	UREA CYCLE DISORDERS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE	C+V		√		
SOFOBUVIR/LEDIPASVIR +/- RIBAVIRIN	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA 363	AS PER RUN RATE CARD	AS PER RUN RATE CARD	HEPATITIS C MDS	C+V	√	√		
SOFOBUVIR/PEGINTERFERON+ RIBAVIRIN	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA 330	AS PER RUN RATE CARD	AS PER RUN RATE CARD	HEPATITIS C MDS	C+V	√	√		
SOFOBUVIR/VELPATASVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA 430	AS PER RUN RATE CARD	AS PER RUN RATE CARD	HEPATITIS C MDS	C+V	√	√		
SORAFENIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA 474 & TA 535	NICE	NICE	SACT	C+V	√		√	
STAVUDINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET	C+V			√	
SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	MULTIPLE INDICATIONS	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011) IMMUNOGLOBULIN GUIDELINES PUBLISHED 2019 ON MDSAS WEBSITE	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD NATIONAL IMMUNOGLOBULIN DATA BASE	C+V			√	
SUCROFERRIC OXYDROXIDE	ADULT RENAL DIALYSIS ONLY	NHS ENGLAND	PHOSPHATE BINDING AGENTS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES		Block				√
SUNTINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA169, TA179, TA449	NICE	NICE	SACT	C+V	√ (Only TA449)		√	
SUTIMLIB	PRIMARY COLD AGGLUTININ DISEASE	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		√		
TABALIMAB	SLE	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		√		
TAFAMIDIS	AMYLOIDOSIS	NHS ENGLAND	NEURODEGENERATIVE CONDITIONS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		√		
TALIGLUCERASE ALFA	GAUCHER'S DISEASE	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE	C+V		√		
TARIBAVIRIN	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		√		
TEDUGLUTIDE	SHORT BOWEL SYNDROME	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		√		
TELBIVUDINE	HEPATITIS B	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED (TA154)	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		√		
TEMSIROLIMUS	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED (TA178)	IFR	IFR	SACT	N/A			√	
TENOFOVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS HEPATITIS B +/- OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	TA173 (FOR HEPATITIS B)AGREED REGIONAL GUIDELINES FOR HIV	BHIVA GUIDELINES (8) NICE	BHIVA GUIDELINES (8) NICE	HARS DATASET	C+V			√	
TENOFOVIR ALAFENAMIDE	HEPATITIS B	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A			√	
TENOFOVIR ALAFENAMIDE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16043/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET	C+V			√	
TENOFOVIR ALAFENAMIDE + COBICISTAT + ELVITEGRAVIR + EMTRICITABINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16043/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET	C+V			√	

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	REIMBURSEMENT C+V OR BLOCK	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
TENOFOVIR DISOPROXIL + COBIKISTAT + ELVITEGRAVIR + EMTRICITABINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: F03/Pa/Agreed Regional Guidelines	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET	C+V			✓	
TENOFOVIR + EMTRICITABINE + EFAVIRENZ	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONALGUIDELINES	BHVA GUIDELINES (8)	BHVA GUIDELINES (8)	HARS DATASET	C+V			✓	
TENOFOVIR + EMTRICITABINE + RILPIVIRINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONALGUIDELINES	BHVA GUIDELINES (8)	BHVA GUIDELINES (8)	HARS DATASET	C+V			✓	
TEPRASIRAN	PREVENTION OF DELAYED GRAFT FUNCTION	NHS ENGLAND	RENAL TRANSPLANTATION	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
TEPROTUMUMAB	GRAVES ORBITOPATHY	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
TERIFLUNOMIDE	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA303 NHS ENGLAND POLICY: D04/P/2	NICE	NICE	NICE AUDIT	C+V	✓		✓****	
TERIPARATIDE	OSTEOGENESIS IMPERFECTA	NHS ENGLAND	DRUGS AFFECTING BONE METABOLISM	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY: 16002P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
TERIPARATIDE	MALE AND JUVENILE OSTEOPOROSIS	NHS ENGLAND	DRUGS AFFECTING BONE METABOLISM	NHS ENGLAND CLINICAL COMMISSIONING POLICY STATEMENT 201101P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	Block			✓	
TETRAHYDROBIOPTERIN	PHENYLKETONURIA	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE	C+V		✓		
TEZACAFTOR WITH IVACAFTOR	CYSTIC FIBROSIS	NHS ENGLAND	MICOLYTICS	NHS ENGLAND URGENT POLICY STATEMENT 200810P & 200809P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY	C+V			✓	
TEZEPELUMAB	ASTHMA	NHS ENGLAND	ALLERGEN IMMUNOTHERAPY	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
THALIDOMIDE	CANCER	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA228	NICE	NICE	SACT	C+V			✓	
THROMBOMODULIN, RECOMBINANT HUMAN	PSEUDOANEURYSM	NHS ENGLAND	BLOOD-RELATED PRODUCTS	IPG060	IPG060	NICE		Block			✓	
TIPRANAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONALGUIDELINES	BHVA GUIDELINES (8)	BHVA GUIDELINES (8)	HARS DATASET	C+V			✓	
TOBRAMYCN	CYSTIC FIBROSIS	NHS ENGLAND	ANTIBACTERIAL DRUGS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A01/P/6 TA276	NHS ENGLAND POLICY NICE	NHS ENGLAND POLICY NICE	NHS ENGLAND POLICY NICE AUDIT	Block			✓*	✓*
TOCILIZUMAB	ADULT ONSET STILL'S DISEASE	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 170056P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓		✓	
TOCILIZUMAB	JUVENILE ARTHRITIS-PAEDIATRIC	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/g, TA 373	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓		✓	
TOCILIZUMAB	TAKAYASU ARTERITIS	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16256P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V			✓	
TOCILIZUMAB	GIANT CELL ARTERITIS	NHS ENGLAND	CYTOKINE MODULATORS	TA 512	NICE	NICE	NICE AUDIT	C+V	✓		✓	
TOCILIZUMAB	CYTOKINE RELEASE SYNDROME	NHS ENGLAND	CYTOKINE MODULATORS	AS PER BLUETEQ FORM	AS PER BLUETEQ FORM	AS PER BLUETEQ FORM	BLUETEQ AUDIT	C+V	✓		✓	
TOLVAPTAN	HYPONATRAEMIA IN CANCER	NHS ENGLAND	POSTERIOR PITUITARY HORMONES AND ANTAGONISTS	NHS ENGLAND CLINICAL COMMISSIONING POLICY 16051P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	Block		✓		
TRALOKINUMAB	ASTHMA	NHS ENGLAND	ALLERGEN IMMUNOTHERAPY	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
TRENEMAQOG ALFA	HAEMOPHILIA B	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
TRENTENE	WILSONS DISEASE	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND CLINICAL COMMISSIONING POLICY 170084P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	C+V	✓	✓		
TRIHEPTANOIN	PYRUVATE CARBOXYLASE DEFICIENCY	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
UPRIFOSBUVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
USTEKINUMAB	PLAQUE PSORIASIS IN CHILDREN	NHS ENGLAND	CYTOKINE MODULATORS	TA455	NICE	NICE	NICE AUDIT	C+V	✓	✓		
VADDUSTAT	DIALYSIS-INDUCED ANAEMIA	NHS ENGLAND	DRUGS USED IN HYPOPLASTIC, HAEMOLYTIC, AND RENAL ANAEMIAS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
VALGANICICLOVIR	CYTOMEGALOVIRUS INFECTION	NHS ENGLAND	CYTOMEGALOVIRUS INFECTION	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY	Block				✓
VANDETANIB	THYROID CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED (TA550)	IFR	IFR	SACT	N/A		✓		
VATQUINONE	FRIEDREICHS ATAXIA	NHS ENGLAND	NEURODEGENERATIVE CONDITIONS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
VELAGLUCERASE ALFA	GAUCHER'S DISEASE	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE	C+V		✓		
VELCALCETIDE	HYPERPARATHYROIDISM	NHS ENGLAND	DRUGS AFFECTING BONE METABOLISM	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
VELMANASE ALFA	ALPHA MANNOSIDASE DEFICIENCY	NHS ENGLAND	DRUGS USED TO TREAT ALPHA MANNOSIDOSIS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
VEMURAFENIB	MELANOMA	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA269	NICE	NICE	NICE AUDIT	C+V		✓		
VESTRONIDASE ALFA	MUCOPOLYSACCHARIDOSIS VII	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
VOLANESORSEN	FAMILIAL CHYLOMICRONAEMIA SYNDROME	NHS ENGLAND	LIPID-REGULATING DRUGS	HST13	NICE	NICE	NICE AUDIT	C+V	✓	✓		
VONICOG ALFA	VON WILLEBRAND DEFICIENCY	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NHS ENGLAND CLINICAL COMMISSIONING POLICY:200801P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	C+V		✓		
VON WILLEBRAND FACTOR, RECOMBINANT	VON WILLEBRAND DEFICIENCY	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	C+V		✓		
VORETIGENE NEPARVOVEC	INHERITED RETINAL DYSTROPHIES	NHS ENGLAND	RETINAL DISORDERS/INTRAOCULAR LENS REPLACEMENT SURGERY	HST11	NICE	NICE	NICE AUDIT	C+V	✓	✓		
VORICONAZOLE	FUNGAL INFECTION	NHS ENGLAND	ANTIFUNGALS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY	Block				✓
VORICONAZOLE	CHRONIC PULMONARY ASPERGILLOSIS	NHS ENGLAND	ANTIFUNGALS	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY		Block		✓		
VOXELOTOR	SICKLE CELL DISEASE	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
VX-210	SPINAL CORD INJURY	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
ZICONOTIDE	INTRATHECAL ANALGESIA	NHS ENGLAND	NON-OPIOD ANALGESICS	NOT ROUTINELY COMMISSIONED - NHS ENGLAND POLICY 16011P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
ZIDOVIDUINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONALGUIDELINES	BHVA GUIDELINES (8)	BHVA GUIDELINES (8)	HARS DATASET	C+V			✓	
ZIDOVIDUINE + LAMIVUDINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONALGUIDELINES	BHVA GUIDELINES (8)	BHVA GUIDELINES (8)	HARS DATASET	C+V			✓	
ZIDOVIDUINE + LAMIVUDINE + ABACAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTI-RETROVIRALS	AGREED REGIONALGUIDELINES	BHVA GUIDELINES (8)	BHVA GUIDELINES (8)	HARS DATASET	C+V			✓	
OTHER DRUGS NOT LISTED UNDER PBR EXCLUSIONS												
3,4 DIAMINOPYRIDINE	LAMBERT EATON MYASTHENIC SYNDROME	NHS ENGLAND		AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES		C+V		✓		
ABEMACICLIB	CANCER	CDF	CANCER EXCLUSION	TA563 CDF TA579	NICE CDF	NICE CDF	SACT	C+V	✓	✓		

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	REIMBURSEMENT C+V OR BLOCK	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
ALBUMIN BOUND PACLITAXEL	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 476	NICE	NICE	SACT	C+V	✓		✓	
ALECTINIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 536	NICE	NICE	SACT	C+V	✓		✓	
ARSENIC TRIOXIDE	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 628 NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY STATEMENT 170072P	NICE	NICE	SACT	C+V	✓		✓	
ATEZOLIZUMAB	CANCER	NHS ENGLAND/ CDF	CANCER EXCLUSION	TA520, TA523, TA584, TA639, TA638, TA666, TA665, CDF TA 466	NICE CDF	NICE CDF	SACT	C+V	✓		✓	
AUTOLOGOUS CHONDROCYTE IMPLANTATION	ARTICULAR CARTILAGE DEFECT	NHS ENGLAND		TA 477 & TA 508	NICE	NICE	NICE AUDIT	C+V	✓	✓		
AVELLUMAB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 517 CDF (TA645)	NICE CDF	NICE CDF	SACT	C+V	✓		✓	
AXICABTAGENE CIOLELUCEL	CANCER	CDF	ATMP	TA 559	CDF	CDF	SACT	C+V	✓	✓		
AZATHIOPRINE	TRANSPLANT IMMUNOSUPPRESSION ONLY	NHS ENGLAND		NEW PATIENTS ONLY UNTIL FORMAL REPATRIATION AGREED TA216	TRUST GUIDELINES	TRUST GUIDELINES		C+V			✓*	✓*
BENDAMUSTINE	CANCER	NHS ENGLAND/ CDF	CANCER EXCLUSION	CDF POLICY NHS ENGLAND POLICY (WITH RITUXIMAB) 170055P, 17088P, 170054P, 200604P & 200701P	NICE CDF NHS ENGLAND POLICY	NICE CDF NHS ENGLAND POLICY	SACT	Block	✓ (Not for all policies)		✓	
BINIMETINIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA562	NICE	NICE	SACT	C+V	✓		✓	
BLINATUMOMAB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA450, TA589	NICE	NICE	SACT	C+V	✓		✓	
BRENTUXIMAB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA446 (replaced by TA524), TA478, TA524, TA577, TA641	NICE	NICE	SACT	C+V	✓		✓	
BRIGATINIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA571, TA670	NICE	NICE	SACT	C+V	✓		✓	
CABAZITAXEL	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 391	NICE	NICE	SACT	C+V	✓		✓	
CABOZANTINIB	CANCER	NHS ENGLAND/CDF	CANCER EXCLUSION	TA 463, TA516 & TA 542	NICE	NICE	SACT	C+V	✓		✓	
CARFILZOMIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 467, TA657	NICE	NICE	SACT	C+V	✓		✓	
CEMLUMAB	CANCER	CDF	CANCER EXCLUSION	TA 592 (CDF)	CDF	CDF	SACT	C+V	✓		✓	
CERTINIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 395, TA 500	NICE	NICE	SACT	C+V	✓		✓	
CHEMOTHERAPY	CANCER - (NOT SPECIFICALLY LISTED)	NHS ENGLAND/ CDF	CANCER EXCLUSION	TRUST GUIDELINES/ NICE/ CDF POLICY	TRUST GUIDELINES/ NICE/ CDF POLICY	TRUST GUIDELINES/ NICE/ CDF POLICY	SACT	Block			✓	
CICLOSPORIN	TRANSPLANT IMMUNOSUPPRESSION ONLY	NHS ENGLAND		NEW PATIENTS ONLY UNTIL FORMAL REPATRIATION AGREED	TRUST GUIDELINES	TRUST GUIDELINES	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED	C+V			✓*	✓*
CLOFARABINE	CANCER	CDF	CANCER EXCLUSION	CDF POLICY NOT ROUTINELY COMMISSIONED - NHS ENGLAND POLICY 170060P	CDF	CDF	SACT	C+V			✓	
COLESTILAN	ADULT RENAL DIALYSIS ONLY	NHS ENGLAND		DRUGS FOR MINERAL BONE DISORDERS TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES		Block				✓
DACOMITINIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA595	NICE	NICE	SACT	C+V	✓		✓	
DARATUMUMAB	CANCER	CDF	CANCER EXCLUSION	CDF (TA 510, TA 573)	CDF	CDF	SACT	C+V	✓		✓	
DAROLUTAMIDE	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 650	NICE	NICE	SACT	C+V	✓		✓	
DINLUXIMAB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 538	NICE	NICE	SACT	C+V	✓		✓	
DOCETAXEL	CANCER	NHS ENGLAND	CANCER EXCLUSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY STATEMENT B15/PS/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	SACT	Block			✓	
DURVALUMAB	CANCER	CDF	CANCER EXCLUSION	CDF TA578	CDF	CDF	SACT	C+V	✓	✓		
ENCORAFENIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA562, TA668	NICE	NICE	SACT	C+V	✓		✓	
ENTRECTINIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA643 AND CDF (TA644)	NICE CDF	NICE CDF	SACT	C+V	✓		✓	
ERIBULIN	CANCER	NHS ENGLAND	CANCER EXCLUSION	NICE TA 423	NICE	NICE	SACT	C+V	✓		✓	
FACTOR X (COAGADEX)	HEREDITARY FACTOR X DEFICIENCY	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
GEMCITABINE (WITH CAPECITABINE)	CANCER	NHS ENGLAND	CANCER EXCLUSION	NHS ENGLAND POLICY 170101P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	SACT	Block	✓	✓		
GEMTUMUMAB OZOGAMICIN	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 545	NICE	NICE	SACT	C+V	✓	✓		
GILTERRITINIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 642	NICE	NICE	SACT	C+V	✓		✓	
IBRUTINIB	CANCER	NHS ENGLAND/CDF	PROTEIN KINASE INHIBITORS	TA429, TA502 CDF (TA491)	NICE CDF	NICE CDF	SACT	C+V	✓		✓	
IDELALISIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NICE TA 568	NICE	NICE	SACT	C+V	✓		✓	
INOTUZUMAB OZOGAMICIN	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 541	NICE	NICE	SACT	C+V	✓	✓		
IPILIMUMAB	CANCER	NHS ENGLAND/CDF	CANCER EXCLUSION	TA268, TA319, TA400, CDF TA581	NICE CDF	NICE CDF	SACT	C+V	✓		✓	
ISATUXIMAB	CANCER	NHS ENGLAND	CANCER EXCLUSION	CDF (TA 658)	CDF	CDF	SACT	C+V	✓		✓	
LAROTRECTINIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	CDF (TA 628)	CDF	CDF	SACT	C+V	✓		✓	
LENVATINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA498, TA 535 & TA 551	NICE	NICE	SACT	C+V	✓		✓	
LIPosomal CYTARABINE-DAUNORUBICIN	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 522	NICE	NICE	SACT	C+V	✓		✓	
LORLATINIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 628	NICE	NICE	SACT	C+V	✓		✓	
LUTETIUM (177Lu) OXODOTREOTIDE	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 539	NICE	NICE	SACT	C+V	✓	✓		
MESENCHYMAL STEM CELLS (E.G. PROCHYMAL®)	ACUTE GVHD AND OTHER INDICATIONS (BCSH)	NHS ENGLAND		NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
MDOSTAURIN	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 523	NICE	NICE	SACT	C+V	✓		✓	
MYCOPHENOLATE MOFETIL	TRANSPLANT IMMUNOSUPPRESSION ONLY	NHS ENGLAND		TA481, TA482 NEW PATIENTS ONLY UNTIL FORMAL REPATRIATION AGREED	NICE	NICE	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED	C+V	✓		✓*	✓*
MYCOPHENOLIC ACID	TRANSPLANT IMMUNOSUPPRESSION ONLY	NHS ENGLAND		TA481, TA482 NEW PATIENTS ONLY UNTIL FORMAL REPATRIATION AGREED	NICE	NICE	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED	C+V			✓*	✓*
NELARABINE	CANCER	CDF	CANCER EXCLUSION	CDF POLICY	CDF	CDF	SACT	C+V			✓	

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	REIMBURSEMENT C+V OR BLOCK	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
NERATINIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA612	NICE	NICE	SACT	C+V	✓		✓	
NIRAPARIB	CANCER	CDF	CANCER EXCLUSION	CDF (TA 528, TA 673)	CDF	CDF	SACT	C+V	✓		✓	
NIVOLUMAB	CANCER	NHS ENGLAND/CDF	CANCER EXCLUSION	TA 384, 400, 417, 462, 530, 665, 684 CDF (TA 484, TA 490, TA 558, TA 581)	NICE CDF	NICE CDF	SACT	C+V	✓		✓	
OBINUTUZUMAB	CANCER	NHS ENGLAND/CDF	CANCER EXCLUSION	TA343, TA513, TA629 CDF (TA663)	NICE CDF	NICE CDF	SACT	C+V	✓		✓	
OLAPARIB	CANCER	NHS ENGLAND/CDF	CANCER EXCLUSION	TA 381, CDF TA598, TA620	NICE CDF	NICE CDF	SACT	C+V	✓		✓	
OSMERTINIB	CANCER	NHS ENGLAND/CDF	CANCER EXCLUSION	TA653, TA654 CDF (TA 416)	NICE CDF	NICE CDF	SACT	C+V	✓		✓	
PALBOCICLIB	CANCER	NHS ENGLAND/CDF	CANCER EXCLUSION	TA 495 & TA 619 (CDF)	NICE CDF	NICE CDF	SACT	C+V	✓		✓	
PANITUMUMAB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA439	NICE	NICE	SACT	C+V	✓		✓	
PANOBINOSTAT	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 380	NICE	NICE	SACT	C+V	✓		✓	
PEGASPARGASE	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 408	NICE	NICE	SACT	C+V	✓		✓	
PEGYLATED LIPOSOMAL DOXORUBICIN	CANCER	NHS ENGLAND/ CDF	CANCER EXCLUSION	TA81 CDF POLICY	NICE CDF	NICE CDF	SACT	Block			✓	
PEMETREXED	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA135, TA181, TA190, TA 402	NICE	NICE	SACT	C+V			✓	
PEPTIDE RECEPTOR RADIONUCLIDEOTIDE THERAPY	CANCER	CDF		NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
PERTUZUMAB	CANCER	NHS ENGLAND	CANCER EXCLUSION	NICE TA 424, TA 509 and TA 569	NICE	NICE	SACT	C+V	✓		✓	
PIXANTRONE	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA308	NICE	NICE	SACT	C+V	✓		✓	
POLATUZUMAB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA649	NICE	NICE	SACT	C+V	✓		✓	
PROTEIN KINASE INHIBITORS	ENDOCRINOLOGY; NON-MALIGNANT CONDITIONS	NHS ENGLAND		NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A		✓		
RADIUM-223 DICHLORIDE	CANCER	NHS ENGLAND	CANCER EXCLUSION	NICE TA 376 replaced by TA 412	NICE	NICE	SACT	C+V	✓	✓		
RAMICIRUMAB	CANCER	NHS ENGLAND	CANCER EXCLUSION	NOT ROUTINELY COMMISSIONED - TA 378	AS PER IFR APPROVAL	AS PER IFR APPROVAL	SACT	C+V		✓		
RIBOCICLIB	CANCER	NHS ENGLAND/CDF	CANCER EXCLUSION	TA 496, TA687	NICE	NICE	SACT	C+V	✓		✓	
RUCAPARIB	CANCER	NHS ENGLAND/CDF	CANCER EXCLUSION	CDF TA611	CDF	CDF	SACT	C+V	✓		✓	
STRIMVELIS	ADENOSINE DEAMINASE DEFICIENCY; SEVERE COMBINED IMMUNODEFICIENCY	NHS ENGLAND	ATMP	HST7	NICE	NICE	NICE AUDIT	C+V		✓		
TACROLIMUS	TRANSPLANT IMMUNOSUPPRESSION ONLY	NHS ENGLAND		TA481, TA482 NEW PATIENTS ONLY UNTIL FORMAL REPATRIATION AGREED	NICE	NICE	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED	C+V			✓*	✓*
TALIMOGENE LAHERPAREPVEC	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 410	NICE	NICE	SACT	C+V	✓	✓		
TEMOZOLOMIDE	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA23 & TA121 NHS ENGLAND POLICY 200203P	NICE NHS ENGLAND POLICY	NICE NHS ENGLAND POLICY	SACT	Block	✓	✓		
TEMOZOLOMIDE	ENDOCRINOLOGY; NON-MALIGNANT CONDITIONS	NHS ENGLAND	CANCER EXCLUSION	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	N/A			✓	
TISAGENLECLEUCEL	CANCER	CDF	ATMP	CDF (TA 554, TA 567)	NICE CDF	NICE CDF	SACT	C+V	✓	✓		
TIVOZANIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 512	NICE	NICE	SACT	C+V	✓		✓	
TRABECTEDIN	CANCER	NHS ENGLAND	ANTI-NEOPLASTIC DRUGS	TA185	NICE	NICE	SACT	C+V	✓		✓	
TRAMETINIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 396 & TA 544	NICE	NICE	SACT	C+V	✓		✓	
TRASTUZUMAB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 34, 107, 209	NICE	NICE	SACT	C+V	✓		✓	
TRASTUZUMAB EMTANSINE	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 458, TA632	NICE	NICE	SACT	C+V	✓		✓	
TRIFLURIDINE-TIPRACIL	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 405	NICE	NICE	SACT	C+V	✓		✓	
URIDINE TRIACETATE	TREATMENT OF TOXICITY WITH 5-FU AND CAPECITABINE	NHS ENGLAND	CANCER EXCLUSION	NHS ENGLAND URGENT POLICY STATEMENT 1929	NHS ENGLAND POLICY	NHS ENGLAND POLICY		C+V	✓		✓	
VENETOCLAX	CANCER	NHS ENGLAND/CDF	CANCER EXCLUSION	TA 487, TA663 CDF	NICE CDF	NICE CDF	SACT	C+V	✓		✓	

* DRUG IS BEING REPATRIATED FROM PRIMARY TO SECONDARY CARE THEREFORE SUPPLY ROUTE MAY VARY AT PRESENT

** ROUTINELY COMMISSIONED IN COMBINATION WHEN DUAL THERAPY REQUIRED

*** ONLY WHEN PRESCRIBED IN AN ADULT SPECIALIST CENTRE

**** ONLY WHERE IT IS A RECOGNISED MS CENTRE WITH SPECIALIST NURSE SUPPORT

NEW LINES ADDED TO V16 LIST
CHANGES TO V15 2021 LIST

ADDITIONAL NOTES:

- WHERE THE FUNDED INDICATION IS FOR PAEDIATRIC USE THE CCG WILL BECOME THE RESPONSIBLE COMMISSIONER WHEN THE PATIENT IS TRANSFERRED TO THE ADULT SERVICE
- CCGS ARE THE RESPONSIBLE COMMISSIONER FOR RITUXIMAB IN ADULT NON CANCEROUS HAEMATOLOGICAL CONDITIONS (EG ITP) AND NON SPECIALIST AUTO-INFLAMMATORY CONDITIONS (EG RA)
- ELTROMBOPAG AND ROMIPLOSTIM ARE THE RESPONSIBILITY OF CCGS REGARDLESS OF THE CAUSE OF THE THROMBOCYTOPENIA IN ADULTS (PAEDIATRICS ARE NHS ENGLAND RESPONSIBILITY)
- IT IS A MANDATED REQUIREMENT THAT ALL USE OF CHEMOTHERAPY IS RECORDED IN THE SACT DATABASE INCLUDING THOSE TREATMENTS FUNDED THROUGH THE CDF
- USE IN VASCULAR DISEASE IS COMMISSIONED BY NHS ENGLAND WITHIN SPECIALIST CENTRES - CCG'S ARE RESPONSIBLE FOR ALL OTHER INDICATIONS
- NHS ENGLAND IS THE RESPONSIBLE COMMISSIONER WHEN SOMATROPIN ANALOGUES (GROWTH HORMONE) ARE PRESCRIBED IN SPECIALIST CENTRES FOR INDICATIONS FALLING OUTSIDE NICE GUIDANCE

7. NHS ENGLAND COMMISSIONS ARV'S AS PER PUBLISHED POLICIES. FOR THE TREATMENT OF PEOPLE WITH DIAGNOSED HIV INFECTION AND FOR THOSE THOUGHT TO BE HIV POSITIVE (POST EXPOSURE PROPHYLAXIS). NHS ENGLAND DOES NOT ROUTINELY COMMISSION PRE-EXPOSURE PROPHYLAXIS AND THIS IS ONLY AVAILABLE TO THOSE ENROLLED IN CLINICAL STUDIES OR OTHER NHS ENGLAND AGREED SCHEMES

8. DRUGS APPROVED BY NICE FOR ADULT CONDITIONS WILL BE COMMISSIONED IN CHILDREN AT SPECIALISED PAEDIATRIC CENTRES IF THE PATIENT MEETS THE NICE CRITERIA AND THERE IS EVIDENCE TO SUGGEST THAT THE DRUG IS SAFE AND CLINICALLY APPROPRIATE TO USE IN CHILDREN AS PER THE NHS ENGLAND MEDICINES FOR CHILDREN POLICY FOUND AT <https://www.england.nhs.uk/publication/commissioning-medicines-for-children-specialised-services/> AND A BLUETEO FORM IS AVAILABLE. THIS INCLUDES FOR DRUGS NORMALLY COMMISSIONED BY CCG'S IN ADULTS EG ADALIMUMAB, ETANERCEPT, INFILIXIMAB ETC PLEASE NOTE THAT MEDICINES FUNDED UNDER THE NHS ENGLAND MEDICINES FOR CHILDREN POLICY MAY HAVE ADDITIONAL CRITERIA WITH RESPECT TO ACCESS

9. PLEASE NOTE THIS IS A NOT LIVE LIST AND THE COMMISSIONING POSITION MAY CHANGE PRIOR TO A NEW LIST BEING PUBLISHED IN MARCH OF EACH YEAR - REFER TO THE NICE POLICY PROGRAMME ON THE NICE WEBSITE AND/OR THE NHS ENGLAND POLICY PROGRAMME PUBLISHED AT <https://www.england.nhs.uk/publication/clinical-commissioning-policy-work-programme/>

10. Products that are currently available via the Early Access to Medicines Scheme are not covered by this list but all require registration via the Bluetec system

11. Cinacalcet is only excluded to tariff when used to treat secondary hyperparathyroidism

12. Interim policies for use during COVID-19 are not included on this list - to view these policies go to <https://www.england.nhs.uk/coronavirus/clinical-policy/>